Results 81 to 90 of about 20,867 (266)

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects

Frontiers in Endocrinology
IntroductionIncretin-based drugs are extensively utilized in the treatment of type 2 diabetes (T2D), with remarkable clinical efficacy. These drugs were developed based on findings that the incretin effect is reduced in T2D.
Akihiro Hamasaki, Akihiro Hamasaki, Norio Harada, Atsushi Muraoka, Shunsuke Yamane, Erina Joo, Kazuyo Suzuki, Nobuya Inagaki   +7 more
doaj   +1 more source

Incretin levels 1 month after laparoscopic single anastomosis gastric bypass surgery in non-morbid obese type 2 diabetes patients

Asian Journal of Surgery, 2014
Purpose: Bariatric surgery is an efficient procedure for the remission of type 2 diabetes (T2DM) from morbid obesity. However, in Asian countries, the mean body mass index (BMI) of T2DM patients is about 25 kg/m2.
Myung Jin Kim, Hyeong Kyu Park, Dong Won Byun, Kyo Il Suh, Kyung Yul Hur   +4 more
doaj   +1 more source

Incretin hormones and obesity

The Journal of Physiology
Abstract The incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play critical roles in co‐ordinating postprandial metabolism, including modulation of insulin secretion and food intake.
Constanza Alcaino, Frank Reimann, Fiona M. Gribble   +2 more
openaire   +3 more sources

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

From narratives to numbers and back: Assessing the psychosocial aspects of diabetes in the era of high technology with emerging qualitative and quantitative methodologies

Diabetic Medicine, EarlyView.
Abstract Aims Rapid changes in diabetes therapy combined with limitations of traditional methodological approaches challenge the field of psychosocial research to adequately capture the experiences of people with diabetes. This narrative review provides an overview of emerging qualitative and quantitative approaches that can advance the study of ...
Dominic Ehrmann, Eloise Litterbach, Sonya Deschenes, Rita Forde, Norbert Hermanns, Maaike Horsselenberg, Mandy Jansen, Amy McInerney, Eimear Morrissey, Andreas Schmitt, Uffe Søholm, Giesje Nefs   +11 more
wiley   +1 more source

Impact of Incretin Mimetics on Thyroid Cancer Among Patients with Type 2 Diabetes: A Retrospective Cohort Time-to-Event Analysis

Pharmacoepidemiology
Background: Incretin mimetics, including glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonist) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been increasingly utilized for glycemic control in patients with type 2 diabetes (T2D ...
Michael W. Strand, Daniel Chow, Weining Shen, Jonathan H. Watanabe   +3 more
doaj   +1 more source

Dual Glucagon and GLP‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
Elif I. Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla Martinez, Anita M. Hennige, Corinna Schoelch   +5 more
wiley   +1 more source